DAIC

JUNE 4, 2024

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104

Medicare Plaque Reimbursement Technology 104

CardiacWire

MARCH 24, 2024

Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.

Medicare 59

Medicare Obesity CMS Medicaid 59

Cardiovascular Diabetology

JULY 7, 2024

Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce.

Diabetes 72

Diabetes Cardiovascular Disease Drug Costs Medicaid 72

American College of Cardiology

JANUARY 3, 2025

The Centers for Medicare and Medicaid Services (CMS) created two new G codes in the 2025 Medicare Physician Fee Schedule final rule that will provide reimbursement for atherosclerotic cardiovascular disease (ASCVD) risk assessment and risk management services.

Reimbursement 49

Reimbursement Medicare CMS Medicaid 49

DAIC

JULY 18, 2024

CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. In accordance with the AMA semi-annual early release schedule, the new codes will be effective January 1st, 2025 and published in the 2025 CPT Code book.

Reimbursement 105

Reimbursement Electrocardiogram Technology Medicaid 105

American College of Cardiology

FEBRUARY 1, 2025

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. All are members of ACC’s Cardiovascular Team Member Section.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

DAIC

JUNE 18, 2024

We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S. patients as soon as possible to elevate the standard of care for cardiovascular disease treatment.” “The

Coronary Artery Disease 105

Coronary Artery Disease Technology Stent Stents 105